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Abstract
Introduction Oestrogen exposure is a central factor in the
development of breast cancer. Oestrogen receptor alpha
(ESR1) is the main mediator of oestrogen effect in breast
epithelia and has also been shown to be activated by epidermal
growth factor (EGF). We sought to determine if common
genetic variation in the ESR1 and EGF genes affects breast
cancer risk, tumour characteristics or breast cancer survival.
Methods We genotyped 157 single nucleotide polymorphisms
(SNPs) in ESR1 and 54 SNPs in EGF in 92 Swedish controls
and selected haplotype tagging SNPs (tagSNPs) that could
predict both single SNP and haplotype variation in the genes
with an R2 of at least 0.8. The tagSNPs were genotyped in
1,590 breast cancer cases and 1,518 controls, and their
association with breast cancer risk, tumour characteristics and
survival were assessed using unconditional logistic regression
models, Cox proportional hazard models and haplotype analysis.
Results The single tagSNP analysis did not reveal association
evidence for breast cancer risk, tumour characteristics, or
survival. A multi-locus analysis of five adjacent tagSNPs
suggested a region in ESR1  (between rs3003925 and
rs2144025) for association with breast cancer risk (p = 0.001),
but the result did not withstand adjustment for multiple
comparisons (p = 0.086). A similar region was also implicated
by haplotype analyses, but its significance needs to be verified
by follow-up analysis.
Conclusion Our results do not support a strong association
between common variants in the ESR1 and EGF genes and
breast cancer risk, tumour characteristics or survival.
Introduction
Breast cancer is the most common cancer in women overall
worldwide. Oestrogen exposure is a central factor in the devel-
opment and progression of this cancer [1-3] and its effects on
the breast epithelium is primarily mediated by oestrogen
receptor alpha (ESR1) [4]. In addition to being activated by
oestrogen, the ESR1 protein can be activated by growth fac-
tors such as epidermal growth factor (EGF) [3], which acts as
a potent mitogen for epithelial cells, including mammary epi-
thelia [5]. Variation in the ESR1 (MIM 133430) and EGF (MIM
131530) genes affecting the function or expression of their
respective proteins could thus potentially affect the risk of
developing breast cancer, characteristics of the tumour or the
risk of dying from the disease.
With regard to breast cancer risk or survival, a number of sin-
gle nucleotide polymorphisms (SNPs) have been studied in
the ESR1 gene, yet none have previously been investigated in
the EGF gene. As far as we are aware, no attempt to capture
the common genetic variation in the ESR1 gene in its entirety
has yet been published. One group, who genotyped 17 SNPs
in the ESR1 gene, found a decreased risk of breast cancer for
carriers of three common haplotypes in the gene and an
EGF = epidermal growth factor; ESR1 = (o)estrogen receptor 1; HWE = Hardy-Weinberg equilibrium; LD = linkage disequilibrium; MAF = minor 
allele frequency; NPI = Nottingham Prognostic Index; PLEM = partition ligation expectation maximisation; SNP = single nucleotide polymorphism; 
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increased risk for carriers of one common haplotype [6]. We
genotyped 157 SNPs in ESR1 and 54 SNPs in EGF using a
population-based case-control study, which included 1,590
breast cancer cases and 1,518 controls. We selected haplo-
type-tagging SNPs (tagSNPs) spanning the ESR1 and EGF
genomic regions and assessed their association with breast
cancer risk, the Nottingham Prognostic Index (NPI) and breast
cancer survival.
Patients and methods
Parent breast cancer study
The study base included all Swedish-born women between 50
and 74 years of age and resident in Sweden between October
1993 and March 1995. During this period, all breast cancer
cases were identified at diagnosis through the six regional
cancer registries in Sweden. Controls were randomly selected
from the Swedish Registry of Total Population to match the
cases in 5-year age strata. Of the eligible cases and controls,
3,345 (84%) breast cancer cases and 3,454 (82%) controls
participated in this initial questionnaire-based study.
Present breast cancer study
From the parent study, we randomly selected 1,500 breast
cancer cases and 1,500 age- and frequency-matched con-
trols among the postmenopausal participants without any pre-
vious malignancy (except carcinoma in situ of the cervix or
non-melanoma skin cancer). With the intention of increasing
statistical power in subgroup analyses, we further selected all
remaining breast cancer cases and controls that had used
menopausal hormones (oestrogen alone or any combination of
oestrogen and progestin) for at least 4 years. We also
included all remaining participants with self-reported diabetes
mellitus. In total, we selected 1,801 breast cancer cases and
2,057 controls.
Following informed consent, participants donated whole
blood. For deceased cases and those cases that declined to
donate blood but consented to our use of tissue, we collected
archived paraffin-embedded, non-cancerous tissue samples.
We acquired 70% of the requested tissue samples; the main
reason for non-participation was unwillingness or lack of time
at the respective pathology department to provide the tissue
blocks. In total, we obtained blood samples and archived tis-
sue samples for 1,321 and 275 breast cancer patients,
respectively, and blood samples for 1,524 controls. Popula-
tion-based participation rates (taking into account the propor-
tion that did not participate in the parent questionnaire study)
were 75% and 61% for the cases and controls, respectively.
We extracted DNA from 4 ml of whole blood using the
QIAamp DNA Blood Maxi Kit (Qiagen, Hilden, Germany)
according to the manufacturer's instructions. From non-malig-
nant paraffin-embedded tissues, DNA was extracted using a
standard phenol/chloroform/isoamyl alcohol protocol [7]. We
successfully isolated DNA from 1,318 (blood) and 272 (tis-
sue) breast cancer patients and 1,518 controls. We randomly
selected 92 out of the 1,518 controls to be used for linkage
disequilibrium characterisation and haplotype reconstruction
of the ESR1 and EGF genes.
This study was approved by the Institutional Review Boards in
Sweden and at the National University of Singapore.
SNP markers and genotyping
We selected SNPs in the ESR1 and EGF genes and their 20
kb flanking sequences from dbSNP (build 124, [8]) and Cel-
era databases, aiming for an initial marker density of at least
one SNP per 5 kb. The PvuII (rs2234693), XbaI (rs9340799),
codon 243 (rs4986934) and codon 325 (rs1801132) vari-
ants were selected from the literature and added to our SNP
selection. SNPs were genotyped using the Sequenom primer
extension-based assay (San Diego, CA, USA) and the Bead-
Array system from Illumina (San Diego, CA, USA) following the
manufacturers' instructions. All genotyping plates included
positive and negative controls, DNA samples were randomly
assigned to the plates, and all genotyping results were gener-
ated and checked by laboratory staff unaware of case-control
status. Only SNPs where more than 85% of the samples gave
a genotype call were analysed further. As quality control, we
genotyped 200 randomly selected SNPs in the 92 control
samples using both the Sequenom system and the BeadArray
system. The genotype concordance was > 99.5%, suggesting
high genotyping accuracy.
Linkage disequilibrium characterisation and tagSNP 
selection
We genotyped a dense set of SNPs in the ESR1 and EGF
genes in the 92 controls (Supplementary Tables 1 and 2 in
Additional File 1, respectively). We identified regions of link-
age disequilibrium (LD) and selected tagSNPs. We produced
LD plots of the D' and R2 values for ESR1 and EGF (Supple-
mentary Figures 1 and 2 in Additional File 1, respectively)
using the LDheatmap function in the statistical software R [9].
We reconstructed haplotypes using the partition ligation
expectation maximisation (PLEM) algorithm [10] implemented
in the tagSNPs program [11] and selected tagSNPs based on
the R2 coefficient, described previously (equation (1) in [12].
In our case this is the squared correlation between the true
number of haplotypes (defined across all SNPs typed in the 92
controls) and the number of copies of haplotypes predicted as
being carried, based on the tagSNPs. The R2 coefficient in
[12] can also be used for measuring association between the
genotypes of all SNPs typed in the 92 controls and the geno-
types predicted on the basis of knowing the tagSNPs only.
We chose tagSNPs so that common SNP genotypes (minor
allele frequency ≥ 0.03) and common haplotypes (frequency ≥
0.03) were predicted with R2 ≥ 0.8 [13]. The well studied PvuII
(rs2234693),  XbaI (rs9340799), codon 243 (rs4986934)
and codon 325 (rs1801132) variants were included as tag-
SNPs. In order to evaluate our tagSNPs' performance inAvailable online http://breast-cancer-research.com/content/10/1/R15
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capturing unobserved SNPs within the genes and to assess
whether we needed a denser set of markers, we performed a
SNP-dropping analysis [12,14]. In brief, each of the geno-
typed SNPs was dropped in turn and tagSNPs were selected
from the remaining SNPs so that their haplotypes predicted
the remaining SNPs with an R2 value of 0.85. We then esti-
mated how well the tagSNP haplotypes of the remaining SNPs
predicted the dropped SNP, an evaluation that can provide an
unbiased and accurate estimate of tagSNP performance
[12,14].
There were 19 SNPs upstream of the first tagSNP (TAG1) in
ESR1 (Supplementary Table 1 in Additional File 1). Of the 19,
12 were either not polymorphic or had a minor allele frequency
(MAF) of less than 3%. The remaining seven SNPs in this area
were included in our LD identification and tagSNP selection
analysis. Hence, all polymorphic SNPs with a MAF ≥ 3% far 5'
upstream of ESR1 were captured by our tagSNPs.
Breast tumour characteristics and follow-up
We retrieved information on date and cause of death until 31
December 2003 from the Swedish Causes of Death Registry
and on date of emigration from the Swedish National Popula-
tion Registry. Follow-up time began at date of diagnosis and
ended on 31 December 2003, or at date of death or emigra-
tion, whichever came first.
We collected information on tumour size, lymph node involve-
ment, and grade (tumour differentiation) from medical records
and calculated the Nottingham Prognostic Index (NPI) using
the following formula:
NPI = 0.2 × size [in cm] + 1 × nodal stage [1, 2, or 3] + 1 ×
grade [1, 2, or 3] [15]
Nodal stage was defined as 1 if there were no lymph node
metastases, 2 for a total of 1–3 metastatic nodes, and 3 for
more than 3 metastatic nodes. A tumour of high differentiation
was assigned grade 1, a tumour of intermediate differentiation
grade 2, and a low differentiated tumour was assigned grade
3. We categorised the NPI into two groups: ≤ 4 or > 4. Four
is the mean NPI value of the present study. It has also been
shown that breast cancer survival decreases rapidly for NPI
above 4 [15].
Statistical analyses
We applied unconditional logistic regression models for
assessing the association between ESR1 and EGF tagSNPs
and risk of breast cancer (case-control analysis) or the NPI
(case only analysis). Adjusting for age (in 5-year age groups)
did not affect our results. We estimated the hazard ratio of
death due to breast cancer in relation to the genes' tagSNP
using Cox proportional hazards models. The tagSNPs were
included as covariates in the models either one at a time or in
groups of five (codominant main effects only). The latter
method was used for detection of association with haplotypes.
Although it does not require resolution of gametic phase, tests
based on such models can be powerful within regions of
strong LD [16]. Likelihood ratio tests were used to generate p
values for comparing models with or without covariates. We
made adjustments to our test results to account for multiplicity.
We did so for each outcome (risk, NPI, and survival) sepa-
rately. We used a permutation-based approach that controls
the family-wise error rate (probability of rejecting one or more
true null hypotheses of no association). This is based on the
permutation step-down procedure of Westfall and Young [17]
and takes into account the dependence structure of the poly-
morphisms/hypotheses. We also assessed association
between groups of haplotypes and breast cancer risk using
three approaches (each of which resolve gametic phase). We
used the logistic regression expected haplotype dosage
approach of [11], combining rare haplotypes. Since there is no
biological reason to cluster haplotypes on the basis of their fre-
quency, we also employed a Bayesian association mapping
approach [18] that clusters haplotypes according to their
allelic similarity, and a sliding-window approach described by
Li et al. [19].
To estimate power in the risk component of the study, we used
a method described by Chapman et al. [20], which assumes
co-dominant effects at an unobserved locus. To calculate
power for log-additive effects in the survival component of the
study, we used the Quanto program [21] in a similar manner
as Manolio et al. [22]. Analyses were performed using the sta-
tistical software R or the SAS system (v. 9.1, SAS Institute
Inc., Cary, NC, USA). Because lifestyle and reproductive
breast cancer risk factors are unlikely to cause genetic varia-
tion in the genes, we thus did not adjust for them in the
analyses.
Results
Characteristics of participants
Table 1 shows selected characteristics of the cases and con-
trols included in the parent questionnaire-based study and the
current genetic study. Long-term users of menopausal hor-
mone therapy and women with self-reported diabetes mellitus
were oversampled in the current study. Most other character-
istics were statistically significantly different between cases
and controls and reflected established associations.
More case-related information has been provided in our previ-
ous work [23]. The breast cancer cases that participated in
our study via tissue sample donation were on average 1.5
years older (p = 0.0003) than the cases that donated blood.
The former group was also more likely to have been diagnosed
with TNM (tumour, nodes, metastasis) stage 2 or more
advanced cancers (p < 0.0001). Since no significant differ-
ences in genotype frequencies within TNM stage 1, TNM
stage 2 and TNM stages 3 and 4 were evident between theBreast Cancer Research    Vol 10 No 1    Einarsdóttir et al.
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two groups of cases, this difference is unlikely to be a cause
for concern.
Genotyping, LD pattern and coverage
The genotyping results and SNP coverage in the ESR1 and
EGF genes are summarised in Table 2. A dense set of SNPs
in the ESR1 and EGF genes were genotyped in 92 randomly
selected controls (Supplementary Table 1 (ESR1) and Sup-
plementary Table 2 (EGF) in Additional File 1), and only the
SNPs that were in Hardy-Weinberg equilibrium (p > 0.01) and
that were at least 3% in minor allele frequency among the 92
controls were included in LD analysis and tagSNP selection
(Table 2). LD plots created from the SNPs included in our
study are shown in Supplementary Figures 1 (ESR1) and 2
(EGF) in Additional File 1. Using the SNP dropping method
[14], we found that the tagSNPs selected from the included
SNPs could efficiently capture non-genotyped SNPs in the
genes (Table 2).
Association analyses
We selected 52 tagSNPs in ESR1 and 15 tagSNPs in EGF
that could predict the included SNPs and their haplotypes
with an R2 of at least 0.8. The tagSNPs were genotyped in all
cases and controls (Supplementary Table 3 in Additional File
1), but seven tagSNPs in ESR1 and one tagSNP in EGF could
not be genotyped in the cases that participated via tissue sam-
ple donation.
ESR1
For each outcome (breast cancer risk, NPI and breast cancer
survival), we first tested the association of each tagSNP and
then performed a haplotype analysis using a logistic regres-
sion sliding-window approach where five adjacent tagSNPs
were analysed together (without resolution of gametic phase).
The results are summarised in Figure 1 and Supplementary
Table 4 in Additional File 1. Analysis of the 52 tagSNPs in
ESR1 (including the PvuII, XbaI, codon 243 and codon 325
SNPs) did not reveal any association with breast cancer risk,
NPI or breast cancer survival whose statistical significance
withstood multiple testing correction. The strongest signal of
association with breast cancer risk was obtained by the win-
dow analysis including TAGs 26–30 (p = 0.001 and p =
0.086, before and after correction for multiple testing). Within
the region, there were seven common haplotypes that
accounted for 92% of the chromosomes. Including the
expected dosages of common haplotypes and the rare haplo-
types (combined into a single variable) as covariates in a logis-
tic regression model with the most common haplotype as
reference, gave a global p (likelihood ratio test) of 0.0493 in
relation to breast cancer risk (Table 3).
We also explored a sliding-window analysis of haplotypes
using a variable window size. Three haplotypes within the
region from tagSNP 18 to tagSNP 27 were implicated, show-
ing frequency differences between cases and controls (Table
4). The significance of the frequency differences was, how-
ever, not clear, given the large number of haplotypes being
searched in both fixed- and variable-sized sliding-window anal-
Table 1
Selected characteristics of the cases and controls participating in the present and parent breast cancer study
Present Parent
Characteristic No. of cases/controls Cases/controls No. of cases/controls Cases/controls
Mean: Mean:
Age (years) 1,590/1,518 63.4/63.1 2,817/3,111 63.4/64.3
Age at menopause (years) 1,580/1,505 50.4/50.0 2,802/3,093 50.4/50.0
Recent BMI (kg/m2)a 1,581/1,497 25.8/25.5 2,802/3,065 25.8/25.5
Age at first birth (years) 1,352/1,370 25.4/24.7 2,373/2,753 25.3/24.6
Parity 1,590/1,518 1.8/2.2 2,817/3,110 1.8/2.1
Duration of menopausal hormone use (years) Percentage: Percentage:
0 1,058/1,086 67.2/72.7 1,978/2,467 71.4/80.8
< 4 206/190 13.1/12.7 405/330 14.6/10.8
≥ 43 1 1 b/217b 19.8b/14.5b 389/256 14.0/8.4
Self-reported diabetes mellitus (yes/no) 1,588/1,402 9.0b/7.8b 2,810/2,652 6/6.1
Family history (yes/no)c 1,551/1,380 16.1/9.3 2,744/2,607 16.0/9.2
High NPI (≤ 4/> 4) 975/- 55.7/- -/-
BMI, body mass index; NPI, Nottingham Prognostic Index. a At 1 year prior to diagnosis. b Long-term users of menopausal hormones and women 
with diabetes mellitus were oversampled. c Family history is defined as having at least one first degree relative with breast cancer.Available online http://breast-cancer-research.com/content/10/1/R15
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yses. We also used a Bayesian haplotype clustering method
[18], with a fixed window size of six tagSNPs. Interestingly, the
posterior distribution for the position of a possible disease
mutation coincided with the region suggested by both fixed-
and variable-sized haplotype analyses (Supplementary Figure
3 in Additional File 1).
Also, an analysis within groups of diabetes mellitus, menopau-
sal hormone use or family history furthermore did not reveal
any significant evidence for any tagSNP to be associated with
breast cancer risk (data not shown).
EGF
None of the tagSNPs in EGF showed association with breast
cancer risk, NPI, or breast cancer survival that withstood mul-
tiple testing correction (Supplementary Figure 4 in Additional
File 1). This lack of association was supported by the haplo-
type analysis.
Discussion
We had comprehensive SNP coverage of the entire ESR1 and
EGF genes and were thus able to study if there were any com-
mon variants in the genes that showed an association with
breast cancer risk, NPI or breast cancer survival. No associa-
tion was found between common variants in ESR1 and NPI or
breast cancer survival by single tagSNP analysis. A region
between TAG26 (rs3003925) and TAG30 (rs2144025) in
the ESR1 gene showed a signal for association with breast
cancer risk in the multi-locus analysis of five adjacent tag-
SNPs, but the result did not withstand multiple testing correc-
tion. Interestingly, the suggestive evidence from further
haplotype analyses converge to this region, but its significance
needs to be determined by follow-up analysis. None of the
genotyped SNPs within this region were located in exons (all
were in the middle of intron 4–5) and are thus unlikely to affect
ESR1 protein structure. It is still a possibility however that the
SNPs themselves, or one or more SNPs in LD with any of the
SNPs, may effect the regulation of ESR1 protein expression.
In fact, it has been shown that ESR1 protein overexpression is
common in breast cancer [24]. Common variants within the
EGF  gene did not appear to affect the risk of developing
breast cancer, developing a tumour with high NPI, or dying
from the disease.
Our study was a well designed, population-based case-con-
trol study. Case ascertainment and case survival status were
established using the nationwide, high-quality Cancer Registry
and Causes of Death Registry in Sweden. Exposure status of
the participants was determined using genotyping methods
with low error rates from which all results underwent detailed
quality control. We sought to obtain tissue samples from the
deceased cases and those cases that had declined donation
Table 2
Summary statistics on genotyping results and SNP coverage in ESR1 and EGF for 92 Swedish controls
Summary statistics ESR1 EGF
Number of successfully genotyped SNPs 228a 104b
Number of polymorphic SNPs 184 66
Number of common SNPsc 165 55
Number of SNPs deviating from HWEd 81
Number of SNPs included in study 157 54
Gene size (kb) 295.7 99.4
Sequence coverage of included SNPs (kb) 335.1 145.5
Mean spacing between included SNPs (kb) 2.1 2.7
Median spacing between included SNPs (kb) 1.8 2.3
Number of tagSNPs selected 52 15
Average tagSNP prediction of common SNPs included in study (R2)c 0.998 0.987
Coverage evaluatione
Average prediction of dropped SNPs (R2) 0.997 0.948
Percentage of R2 values ≥ 0.7 100 96.3
HWE, Hardy-Weinberg equilibrium; SNP, single nucleotide polymorphism. a See Supplementary Table 1. b See Supplementary Table 2. c 
Common was defined as minor allele frequency ≥ 0.03. d p < 0.01. e SNP dropping method by Weale et al. [14].Breast Cancer Research    Vol 10 No 1    Einarsdóttir et al.
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of a blood sample, and were able to obtain the majority of the
samples requested. The relative minor lack of tissue accessi-
bility is unlikely to be related to our exposure, ESR1 or EGF
genetic variation, as it depended on the inability of the respec-
tive pathology department to retrieve the samples. The tissue
sample availability was therefore random and could not have
lead to selection bias. The main concern is that the non-partic-
ipation of a small number of deceased cases might have
reduced the power of our study, especially for the survival
analysis. Furthermore, a problem might have arisen since we
were not able to genotype seven tagSNPs in ESR1 and one
tagSNP in EGF in the tissue samples. If these eight tagSNPs
were in fact associated with severe disease, the association
with risk of breast cancer death might have been biased
towards null in our study since we did not genotype all the
severe cases. The fact that the results were not different when
we restricted our analyses to the most severe cases among
those who donated blood samples indicates that the eight tag-
SNPs were unlikely to be associated with severe disease.
In the selection stage of our study, we oversampled cases and
controls that were long-term users of menopausal hormones
and those that had self-reported diabetes mellitus. In the case
of an association between the tagSNPs under study and men-
opausal hormone use or diabetes mellitus, this oversampling
might have caused us to detect an artificial association
between the tagSNPs and breast cancer risk. We therefore
assessed if the tagSNPs were associated with menopausal
Figure 1
Association of 52 tagging single nucleotide polymorphisms (tagSNPs) in ESR1 with breast cancer risk, Nottingham Prognostic Index (NPI) and  breast cancer survival Association of 52 tagging single nucleotide polymorphisms (tagSNPs) in ESR1 with breast cancer risk, Nottingham Prognostic Index (NPI) and 
breast cancer survival. Left column: breast cancer risk. Middle column: NPI (case-only analysis). Right column: breast cancer survival. Squares and 
horizontal lines represent odds and hazard (survival analysis) ratios (change in risk with each addition of the rare allele) and their confidence intervals. 
Sizes of the squares reflect the minor allele frequencies. NPI was categorised into ≤ 4 or > 4.Available online http://breast-cancer-research.com/content/10/1/R15
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hormone use or diabetes mellitus. We found no connection
between the factors and conclude that the oversampling is
unlikely to have posed a problem in our study.
Most previous publications regarding the ESR1  gene and
breast cancer risk have included only a few polymorphisms in
the gene. One study, however, genotyped 17 common SNPs
in the ESR1 gene and found three haplotypes to decrease
breast cancer risk and one haplotype that increased the risk
[6]. None of the haplotypes carried SNPs that were located in
the region in ESR1 we found to be associated with breast can-
cer risk. Two of the haplotypes that showed a protective effect
against breast cancer risk (H4 and H6) carried our TAG21
(rs1801132, codon 325) [6]. We were not able to confirm this
association using a window or a haplotype analysis.
The  PvuII (TAG6, rs2234693), XbaI (TAG7, rs9340799),
codon 243 (TAG14, rs4986934) and codon 325 (TAG21,
rs1801132) variants are among the most commonly studied
polymorphisms in the ESR1 gene. The first two have been
suggested in a couple of studies to decrease the risk of
endometrial cancer [25,26] and PvuII might affect breast can-
cer survival depending on oestrogen receptor status of the
tumour [27], but no consistent effect over studies has been
shown for the four variants with regard to breast cancer risk
[19,28-37]. We found no association between these SNPs
and overall breast cancer risk, NPI or breast cancer survival.
Conclusion
We analysed common genetic variation in the ESR1 and EGF
genes in relation to breast cancer risk, tumour characteristics
and breast cancer survival using a comprehensive haplotype
tagging analysis. To our knowledge, this is the first systematic
association study of these two genes for breast cancer sus-
ceptibility and prognosis. We located a region in ESR1 which
showed a moderate signal for association with breast cancer
risk, but were unable to link common variation in the EGF gene
with breast cancer aetiology or prognosis.
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